BioLineRx Delivers Strong Q1 2026 Performance, Initiates Pivotal GLIX1 Trial for Glioblastoma
Jerusalem, Israel - May 27, 2026
BioLineRx, a leading developer of novel therapeutic solutions for major unmet medical needs, reported strong financial results for the first quarter (Q1) of 2026. The company's quarterly performance was highlighted by the initiation of a pivotal phase I/IIa clinical trial for GLIX1, a highly innovative molecule targeting glioblastoma (GBM) and other cancers.
Phil Serlin, Chief Executive Officer of BioLineRx, noted during the company's Q1 2026 financial results conference call that the phase I part of the trial aims to recruit up to 30 patients with recurrent GBM and other high-grade gliomas. The objective is to establish a maximum tolerated dose and/or recommended dose based on safety, pharmacokinetics/pharmacodynamics (PK/PD), and preliminary efficacy.
Speaking at the conference call, Mr. Serlin expressed excitement about the potential of GLIX1, an oral small molecule that selectively targets DNA damage repair in cancer cells by restoring TET2 activity. This mechanism of action has been shown to be effective against a broad range of cancers.
In a significant development for GBM treatment, GLIX1 was found to cross the blood-brain barrier, providing hope that it may show effect where others have failed in this exceedingly difficult indication. The company's extensive preclinical work has demonstrated that GLIX1 achieved robust dose-dependent tumor growth inhibition and survival benefit in several studies in two orthotopic cell-derived xenograft (CDX) models in GBM.
Additionally, new data presented at the company's Q1 2026 financial results conference call showed that GLIX1 demonstrated a robust anti-tumor effect in a newly completed subcutaneous temozolomide-resistant patient-derived xenograft (PDX) model in GBM. In contrast, no effect was observed with temozolomide.
The initiation of the pivotal phase I/IIa clinical trial for GLIX1 is seen as a significant step forward by BioLineRx. The company plans to provide periodic updates on the trial during the second half of 2026, with full results on the dose escalation part expected in 2027. The phase IIa expansion part of the trial will include additional indications and assess the efficacy of GLIX1 in combination with standard of care treatments.
Mr. Serlin highlighted that the broader oncology community is eagerly awaiting the data from this clinical trial, particularly at this year's American Society of Clinical Oncology (ASCO) meeting. Two abstracts featuring GLIX1 have been accepted for online publication and will be showcased during the meeting.
